NYSE: AGL

agilon health, inc.

CIK 0001831097 · Misc Health Services

Large Revenue $5.9B Assets $1.5B as of Jul 19, 2026

Our business is transforming healthcare by empowering the primary care physicians (“PCP”) to be the agents for change in the communities they serve. We believe that PCPs, with their intimate patient-physician relationships, are best positioned to drive meaningful change in quality, cost and patient… About this business →

Each report below shows a 3-bullet preview. Free accounts read 3 full reports a month — narrative summary, section diffs, and EDGAR-cited quotes.

Sign up free

Want to see a complete report first? Today's free report (TRV 10-Q) is open in full — no account needed.

8-K Filed Jun 3, 2026 · Period ending Jun 2, 2026

agilon health holds routine annual meeting; directors elected, auditor and pay approved

3 material changes detected. Sign up free to read the summary.

10-Q Filed May 6, 2026 · Period ending Mar 31, 2026 Red flag

Agilon Health narrowly avoids NYSE delisting via 1-for-25 reverse split; interim CEOs in place

5 material changes detected. Sign up free to read the summary.

Partner

Trade AGL commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

8-K Filed May 6, 2026 · Period ending May 6, 2026

agilon health reports Q1 2026 earnings results

2 material changes detected. Sign up free to read the summary.

8-K Filed Apr 27, 2026 · Period ending Apr 24, 2026

agilon health names Tim O'Rourke CEO with equity tied to $50-$150 stock price targets

5 material changes detected. Sign up free to read the summary.

8-K Filed Mar 30, 2026 · Period ending Mar 30, 2026

agilon health executes 1-for-25 reverse stock split, shares begin trading March 31

4 material changes detected. Sign up free to read the summary.

10-K Filed Feb 25, 2026 · Period ending Dec 31, 2025

Summary not yet generated.

10-Q Filed Nov 4, 2025 · Period ending Sep 30, 2025

Summary not yet generated.

10-Q Filed May 6, 2025 · Period ending Mar 31, 2025

Summary not yet generated.

10-K Filed Feb 25, 2025 · Period ending Dec 31, 2024

Summary not yet generated.

{# Shared IS / BS / CF block. Expects: financial_statements — dict of title → {periods, rows} financial_statements_meta — {source, unit_note} filing — Filing used to build the tables (EDGAR link) Optional: financials_heading — override h2 (default "Financial Statements") financials_subhead — override subhead HTML/text #}

Latest financial statements

From 10-Q filed May 6, 2026 (period ending Mar 31, 2026). SEC XBRL (companyfacts) — not generated by the model.

SEC XBRL

Consolidated Statements of Operations (Unaudited)

Description Q1 ended Mar 31, 2026 Q1 ended Mar 31, 2025
Revenue:
Total revenue / net sales 1,420 1,533
Operating expenses:
General and administrative 54.2 66.0
Total operating expenses 1,416 1,555
Operating income 4.0 (22.1)
Interest expense 1.8 1.5
Other income/(expense), net 16.0 9.3
Income before income taxes 29.9 (1.7)
Income tax expense/(benefit) 0.03 0.2
Net income 48.9 12.1
Basic earnings per share 2.95 0.73
Diluted earnings per share 2.94 0.73

Consolidated Balance Sheets (Unaudited)

Description Mar 31, 2026 Mar 31, 2025
Current assets:
Cash and equivalents 140.0 136.9
Short-term investments 91.4 230.1
Prepaid expenses and other current assets 118.4 42.4
Other current assets 971.3 1,241
Total current assets 1,321 1,651
Property, plant and equipment, net 24.9 28.1
Operating lease right-of-use assets, net 5.2 9.7
Identifiable intangible assets, net 62.4 68.2
Goodwill 24.1
Deferred income taxes and other assets 96.4 161.7
TOTAL ASSETS 1,505 1,933
Current liabilities:
Current portion of long-term debt 14.7 34.9
Other current liabilities 1,258 1,340
Total current liabilities 1,272 1,375
Long-term debt 15.3
Operating lease liabilities 3.4 7.1
Deferred income taxes and other liabilities 35.9 57.9
Total liabilities 1,324 1,433
Shareholders' equity:
Common stock 0.2 4.1
Capital in excess of stated value 2,110 2,070
Accumulated other comprehensive income (loss) 0.5 0.5
Retained earnings (deficit) (1,929) (1,575)
Total shareholders' equity 181.4 500.3
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY 1,505 1,933

Consolidated Statements of Cash Flows (Unaudited)

Description Q1 ended Mar 31, 2026 Q1 ended Mar 31, 2025
Operating Activities:
Net cash from operating activities 23.7 (32.0)
Investing Activities:
Net cash from investing activities 19.3 (23.1)
Financing Activities:
Net cash from financing activities (5.1) (0.2)
Net increase/(decrease) in cash 37.9 (55.2)

Amounts in millions USD; EPS as reported. Line labels are presentation-friendly mappings of filer XBRL tags — not a re-audit of the full statements. Use EDGAR for interactive notes and detail. Interactive statements & notes on EDGAR ↗

View AI report for this filing

About agilon health, inc.

Source: Item 1 (Business) from the 10-K filed February 25, 2026. Description as filed by the company with the SEC.

ITEM 1. Business

Overview

Our business is transforming healthcare by empowering the primary care physicians (“PCP”) to be the agents for change in the communities they serve. We believe that PCPs, with their intimate patient-physician relationships, are best positioned to drive meaningful change in quality, cost and patient experience when provided with the right infrastructure and payment model. Through our combination of the agilon platform, a long-term partnership model with existing physician groups and a growing network of like-minded physicians, we believe we are poised to revolutionize healthcare for seniors across communities throughout the United States (“U.S.”). We believe our purpose-built model provides the necessary capabilities, capital and business model for existing physician groups to create a Medicare-centric, globally capitated line of business. Our model operates by primarily forming risk-bearing entities (“RBEs”) within local geographies, that enter into arrangements with payors providing for monthly payments to manage the total healthcare needs of our physician partners’ attributed patients (or global capitation arrangements). The RBEs also contract with agilon to perform certain functions and enter into long-term professional service agreements with one or more anchor physician groups pursuant to which the anchor physician groups receive a base compensation rate and share in the savings from successfully improving quality of care and reducing costs.

Our company was formed in 2016, and we established our inaugural partnership with an anchor physician group in 2017. Our ability to rapidly build scaled positions in local communities has allowed us to grow to 28 anchor physician groups and 30 geographies as of December 31, 2025. As of December 31, 2025, the PCPs on our platform serve approximately 511,000 MA members and 114,000 Medicare fee-for-service (“FFS”) beneficiaries through nine Accountable Care Organizations (“ACOs”) through our participation in the Centers for Medicare & Medicaid Services’ (“CMS”) Accountable Care Organization Realizing Equity, Access, and Community Health (“ACO REACH”) Model and Medicare Shared Savings Program (“MSSP,” and together with ACO REACH, the “CMS ACO Models”) through its equity method investments.

Read full description ↓

On November 5, 2025, we received written notice (the “Notice”) from the NYSE informing us that we are no longer in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of our common stock was less than $1.00 per share over a consecutive 30 trading-day period ended November 4, 2025 (the “Price Criteria for Capital or Common Stock”).

We can regain compliance at any time within the six-month period following receipt of the Notice if, on the last trading day of any calendar month during the cure period (or the last trading day of the cure period), we have a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the prior 30 trading-day period ending on the last trading day of the applicable calendar month or the cure period. To regain compliance with the Price Criteria for Capital or Common Stock, we are pursuing a reverse stock split, subject to approval by our stockholders. We expect to seek stockholder approval at our special meeting to be held March 17, 2026. Under the NYSE Listed Company Manual, if we determine that we will cure the stock price deficiency by taking an action that will require stockholder approval, such as a reverse stock split, and we receive stockholder approval no later than our next general meeting of stockholders, the price condition will be deemed cured if, following stockholder approval and implementation of the approved action, the share price promptly exceeds $1.00 per share and the share price remains above that level for at least the following 30 trading days. See the risk entitled “The listing of shares of our common stock does not currently comply with the continued listing requirements of the NYSE, and if the NYSE delists our common stock, it could have an adverse impact on the trading, liquidity and market price of our common stock” under “